Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1567-1574

  Ito, Hiroaki ^a   Iida, Mitsuo ^b   Matsumoto, Takayuki ^c   Suzuki, Yasuo ^d   Sasaki, Hidetaka ^e   Yoshida, Toyomitsu ^e   Takano, Yuichi ^e   Hibi, Toshifumi ^f  

^a Kitano Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d TOHO UNIVERSITY   (Japan)

^e ZERIA PHARMACEUTICAL CO LTD   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colonoscopy; Mesalamine; Randomized controlled trial; Ulcerative colitis

Indexed keywords

ETHYL CELLULOSE; EUDRAGIT; MESALAZINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOCHEZIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PH; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIMED DRUG RELEASE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MESALAMINE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956290240     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21193     Document Type: Article

References (16)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385. (Pubitemid 39062279)
2. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):1-16.
3. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:500-523.
4. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196-200. (Pubitemid 17027391)
5. Mardini HA, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987;28:1084-1089.
6. Riley SA, Tavares IA, Bennett A, et al. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988;26:173-177.
7. Sinha A, Ball DJ, Connor AL, et al. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol. 2003;27:56-69. (Pubitemid 37362992)
8. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898. (Pubitemid 17072238)
9. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350-355.
10. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242. (Pubitemid 32776517)
11. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsule for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993;88:1188-1197. (Pubitemid 23219711)
12. Friedman S, Blumberg RS. Inflammatory bowel disease. In: Kasper DL, Braunwald E, Hauser SL, et al, eds. Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill; 2004:1776-1789.
13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
14. Sutherland LR, Robinson M, Onstad G, et al. A double-blind, placebo controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol. 1990;4:463-467.
15. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89-92.
16. Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol. 2008;1:40-45.